KMKatherine L. Morel

Katherine L. Morel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katherine L. Morel has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer

    by Leigh Ellis, Beatriz German, Katherine Morel, Teia Noel, Nadia Boufaied, Deborah Burkhart, Sujun Chen, Felipe Dezem, Xintao Qiu, Henry Long, et al.

    Phenotypic plasticity is a recognized mechanism of therapeutic resistance in prostate cancer (PCa), however current knowledge of driver mechanisms and therapeutic interventions are limited. Using genetically engineered mouse models (GEMMs) devoid of Pten and Rb1, we previously demonstrated the chromatin reprogramming factor enhancer of zeste homolog 2 (EZH2) as an important regulator of alternative transcription programs promoting phenotypic plasticity. Here, using a multi-omics approach we demonstrate that EZH2 regulates multilineage cell states dependent on the RNA binding protein Tristetraprolin (TTP) that mediates RNA stability and activation of translation. Combined chemical inhibition of EZH2 and PI3K/mTORC1 resulted in superior anti-tumor activity in murine and human phenotypic plastic models and was most significant when this combination was used with castration or enzalutamide. Together, these data indicate phenotypic plasticity dependence on coordination between EZH2, TTP and mTORC1 signaling that represent novel therapeutic dependencies for this lethal PCa phenotype.

  • Open Access

    EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer

    by Beatriz German, Katherine L. Morel, Teia Noel, Nadia Boufaied, Deborah L. Burkhart, Sujun Chen, Felipe Dezem, Xintao Qui, Henry W. Long, Stefan DiFazio, et al.

    Phenotypic plasticity is a recognized mechanism of therapeutic resistance in prostate cancer (PCa), however current knowledge of driver mechanisms and therapeutic interventions are limited. Using genetically engineered mouse models (GEMMs) devoid of Pten and Rb1, we previously demonstrated the chromatin reprogramming factor enhancer of zeste homolog 2 (EZH2) as an important regulator of alternative transcription programs promoting phenotypic plasticity. Here, using a multi-omics approach we demonstrate that EZH2 regulates multilineage cell states dependent on the RNA binding protein Tristetraprolin (TTP) that mediates RNA stability and activation of translation. Combined chemical inhibition of EZH2 and PI3K/mTORC1 resulted in superior anti-tumor activity in murine and human phenotypic plastic models and was most significant when this combination was used with castration or enzalutamide. Together, these data indicate phenotypic plasticity dependence on coordination between EZH2, TTP and mTORC1 signaling that represent novel therapeutic dependencies for this lethal PCa phenotype. Graphical Significance Statement: EZH2 plays a key role in driving cell state transitions in neuroendocrine prostate cancer (NEPC), guiding cancer cells towards a more aggressive, therapy-resistant cell type. This transformation creates a specific vulnerability, as NEPC cells become highly reliant on both EZH2 and PI3K/mTORC1-translation signaling. Targeting this dependency, we demonstrate that combining EZH2 with PI3K/mTORC1 inhibition provides effective suppression of NEPC cell growth, offering a promising therapeutic strategy for treating this challenging and aggressive prostate cancer subtype.


  • Open Access

    Radioprotective effects of parthenolide lotion against skin injury caused by radiation (REPAIR-1): protocol for a phase 0, non-randomised, double-blind, interventional pilot study

    by Connor M D Williams, Katherine L Morel, Agnieszka Kumorkiewicz-Jamro, Daniel P Johnstone, Hien V Le, Christopher J Sweeney, Hannah R Wardill

    Introduction Radiation forms the basis of many successful anti-cancer treatment regimens, killing tumour cells by irreversibly damaging their DNA. Unfortunately, radiation indiscriminately kills healthy cells, causing a range of debilitating and highly impactful side effects. One of the most common side effects is damage and burning of the skin, termed radiation-induced dermatitis (RID), which occurs in up to 95% of people undergoing radiation therapy. Although common, RID cannot be prevented and is inadequately managed with various topical solutions. Parthenolide has emerged as a promising radioprotective agent for the management of RID. The REPAIR-1 study is a phase 0, prospective, non-randomised, double-blind, interventional pilot study which aims to assess the efficacy of topical parthenolide application in limiting severe RID. Methods and analysis The REPAIR-1 study will be conducted at the Royal Adelaide Hospital, South Australia, Australia. Eligible participants for the REPAIR-1 study include adults diagnosed with locally advanced cancer of the head/neck scheduled to receive definitive, bilateral radiation therapy. Once enrolled, eligible participants will receive application of a 1% parthenolide, or placebo lotion, to opposite sides of the head/neck region before and after daily radiation therapy for the duration of their treatment course (6-7 weeks). The primary outcome of this study is absolute RID severity after 4 weeks of radiation therapy defined by both CTCAE v5.0 criteria and the RISRAS tool. Ethics and dissemination This protocol has been approved by Central Adelaide Local Health Network Human Research Ethics Committee (2024/HRE00241). All participants will be required to provide written informed consent. Results will be disseminated in peer-reviewed journals, and at scientific conferences. Trial registration number ACTRN12625000456459

  • Open Access

    Supplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    Supplement Figure 2. A. SKO, DKO, and PPKO were cultured as 3-dimensional spheroids and treated with the indicated concentrations of the CDK2 inhibitor - BGG463 over 72 hours. Cell growth was determined by CellTiter-Glo luminescent cell viability assay. B. Western blot analysis for Cdk2, Cdk5, and Vinculin following DKO and PPKO were treated with the indicated concentration of the CDK2 PROTAC - CPS2. Full western blot membranes for C) CDK2, D) CDK5, and E) vinculin.

  • Open Access

    Table S3 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    DEG analysis between DKO Mybl2 KO versus DKO Ctl cells and PPKO Mybl2 KO versus PPKO Ctl

  • Open Access

    Table S2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    Combined genes enriched in human NEPC, PDX samples and NE-like mouse models

  • Open Access

    Supplement Figure 1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    A. Full membrane following CRISPR targeting of Mybl2 indicating specific targeting of our target gene. B. DKO-Ctl and DKO-Mybl2 KO cells were cultured as 2-dimensional monolayers and overall cell growth was determined by CellTiter-Glo luminescent cell viability assay.

  • Open Access

    Table S1 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    Summary of Peak calls following H3K27ac ChIPseq with Atacseq integration.

  • Open Access

    Figure 6 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    Inhibition of CDK2 represents a novel therapeutic target for NEPC. A, Tumoral growth curve of murine DKO cells in C57BL/6N and (B) PPKO cells in C57BL/6N mice and treated with either vehicle control or the CDK2 PROTAC—CPS2. Mice were treated every 7 days (D7 and D14) with CPS2 (400 mg/kg) by intraperitoneal injection. Tumor growth was monitored every second day for 16 days (D16) by serial caliper measurements. Tumoral weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Immunofluorescent IHC staining for CDK2 in DKO and (D) PPKO tumors show that CPS2 inhibition significantly reduces CDK2 expression. E and F, Example pictures of hematoxylin and eosin, Ki67, and p-γH2AX IHC staining in murine DKO and PPKO tumors from the in vivo study and corresponding quantification of the percentage of positive nuclei from total cells (n = 5 mice per treatment group, ±1 SEM).

  • Open Access

    Figure 5 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

    by Beatriz German, Sarah A. Alaiwi, Kun-Lin Ho, Jagpreet S. Nanda, Marcos A. Fonseca, Deborah L. Burkhart, Anjali V. Sheahan, Hannah E. Bergom, Katherine L. Morel, Himisha Beltran, et al.

    Mybl2 is a genetic dependency associated with CDK2 expression in NEPC. A, Tumoral growth curve of murine DKO Ctl and DKO Mybl2 KO cells and (B) PPKO Ctl cells and PPKO Mybl2 KO cells in NOD SCID mice. Tumor growth was monitored by serial caliper measurements every second day for 16 days (D16). Tumor weight was measured at D16 after dissection (n = 5 mice per treatment group (±1 SEM). C, Top responses from the cancer therapeutics response portal analysis using a MYBL2 gene signature. DEMETER gene dependency of CDK family members 2, 5, and 7 across human prostate cancer cell lines indicating as significant, as outlined in Fig. 3A. D, Box plot graphs summarizing the RNA-seq analysis from published prostate cancer GEMMs (first and second graphs, including wild-type, SKO, DKO, NP:Nkx3.1CreERT2:Ptenf/f and NPp53:Nkx3.1CreERT2:Ptenf/f:Trp53f/f), and human samples (third graph, including CRPC and NEPC samples) indicate CDK2 upregulation in NEPC mouse models and human patients. E, Immunofluorescent IHC staining for CDK2 in DKO and (F) PPKO murine tumors indicates a significant loss of CDK2 expression following MYBL2 KO.